Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) is expected to be releasing its Q4 2025 resultson Monday, March 30th. Analysts expect Sagimet Biosciences to post earnings of ($0.4322) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 7:00 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last posted its earnings results on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Price Performance

Sagimet Biosciences stock opened at $4.82 on Monday. The firm has a market capitalization of $157.04 million, a P/E ratio of -3.07 and a beta of 3.35. Sagimet Biosciences has a one year low of $1.73 and a one year high of $11.41. The business has a fifty day moving average price of $5.66 and a 200-day moving average price of $6.52.

Insider Buying and Selling

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total value of $64,861.36. Following the transaction, the chief executive officer directly owned 677,621 shares in the company, valued at $3,632,048.56. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Sagimet Biosciences by 819.2% in the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock worth $29,000 after purchasing an additional 4,391 shares during the last quarter. Virtu Financial LLC purchased a new position in Sagimet Biosciences in the 4th quarter worth approximately $62,000. Bank of America Corp DE increased its holdings in shares of Sagimet Biosciences by 81.8% in the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock worth $76,000 after buying an additional 4,473 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Sagimet Biosciences in the 3rd quarter worth $95,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Sagimet Biosciences during the 1st quarter valued at $105,000. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on SGMT. Barclays began coverage on Sagimet Biosciences in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 target price for the company. Guggenheim began coverage on Sagimet Biosciences in a research report on Tuesday, February 3rd. They set a “buy” rating and a $27.00 price target on the stock. Wall Street Zen upgraded shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Sagimet Biosciences in a research note on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Thursday, January 22nd. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.00.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.